blinatumumab治疗急性淋巴细胞白血病的结构、发展、临床前及临床疗效。

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2015-01-01 DOI:10.2217/fon.15.84

Naresh Bumma, Nikolaos Papadantonakis, Anjali S Advani

{"title":"blinatumumab治疗急性淋巴细胞白血病的结构、发展、临床前及临床疗效。","authors":"Naresh Bumma, Nikolaos Papadantonakis, Anjali S Advani","doi":"10.2217/fon.15.84","DOIUrl":null,"url":null,"abstract":"The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fon.15.84","citationCount":"11","resultStr":"{\"title\":\"Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.\",\"authors\":\"Naresh Bumma, Nikolaos Papadantonakis, Anjali S Advani\",\"doi\":\"10.2217/fon.15.84\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/fon.15.84\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fon.15.84\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon.15.84","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 11

摘要

成人急性淋巴细胞白血病(ALL)的治疗仍然具有挑战性，需要新的治疗方法。抗原CD19在90%以上的b前all细胞中表达，是一个有吸引力的治疗靶点。双特异性t细胞结合抗体blinatumomab靶向CD19，并在最小残留病阳性和复发/难治性前b ALL中显示出令人鼓舞的结果。在这篇综述中，我们详细讨论了blinatumomab的作用机制和关键的药理学方面。并对其临床前研究、临床研究及毒性进行了综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.

The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.